GlassScriptPhysician profile
Keith Hornbrook
NPI 1023784436
$2,763.78
in general payments reported to CMS, 2019-2025
24 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.79 · 2022: $426 · 2023: $589 · 2024: $689 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $475.87 | 2023-2025 | Yeztugo, Epclusa |
| Novo Nordisk INC | $253.30 | 2022-2025 | Rybelsus, Ozempic |
| Collegium Pharmaceutical, INC. | $228.62 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $206.43 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $192.10 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $175.07 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.99 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $144.20 | 2022-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $142.10 | 2024-2025 | |
| Pfizer INC. | $115.59 | 2022-2025 | |
| Amgen INC. | $106.48 | 2023-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $101.96 | 2021-2024 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $90.18 | 2022 | |
| Cequr Corporation | $48.11 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $47.77 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $43.39 | 2022-2025 | Sublocade |
| Alkermes, INC. | $40.99 | 2023-2024 | Vivitrol, Vivitrol |
| Mylan Specialty L.P. | $39.96 | 2024 | Yupelri |
| Braeburn INC. | $35.99 | 2023-2024 | Brixadi |
| Phathom Pharmaceuticals, INC. | $32.64 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.62 | 2023 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $26.51 | 2023-2024 | Tirosint, Licart, Tirosint |
| Otsuka America Pharmaceutical, INC. | $22.77 | 2024 | Rexulti |
| Medtronic, INC. | $19.14 | 2023 | Clydesdale Ptc Spinal System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Hornbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.